Based on research and analysis of the Chinese oncolytic virus therapy market in recent years, as well as studies and evaluations of related companies in the industry, the globally renowned growth consulting firm Frost & Sullivan (Frost & Sullivan, abbreviated as: Frost & Sullivan) awarded Wuhan Binhuai Biotechnology Co., Ltd. (hereinafter referred to as 'Binhuai Biotech') the 'China Oncolytic Virus Therapy Leadership Award', which was presented by Dr. Wang Xin, a global partner of Frost & Sullivan and Chairman of the Greater China Region, to Mr. Liu Binlei, Chairman of Wuhan Binhuai Biotechnology Co., Ltd.
Frost & Sullivan awarded Wuhan Binhuai Biotechnology Co., Ltd.
‘China Oncolytic Virus Therapy Leadership Award’
Dr. Wang Xin presented the award to Mr. Liu Binlei, Chairman of Binhuai Biotech
Binhuai Biotech is a leading biopharmaceutical company in China in the research and development and production of oncolytic virus drugs
Binhuai Biotech was established in 2010 by Dr. Liu Binlei, a key member of the original research team that has approved the market launch of the oncolytic virus T-VEC (Imlygic). It is a national high-tech enterprise specializing in the research and development, production, and technical services of new biological drugs. Currently, the company has established an oncolytic virus immunotherapy platform with independent intellectual property rights and a leading position in the industry, and has established production processes recognized by NMPA and FDA, enabling integrated production and research to meet clinical and industrialization needs.
Multiple oncolytic virus products have entered clinical trials, playing a therapeutic role against various solid tumors
Binhuai Biotech's oncolytic virus candidate drug BS001 (OH2) injection was approved for IND by the Chinese NMPA in 2018, and then received FDA approval in North America on August 20, 2021, to conduct clinical trials for various solid tumors; it then received orphan drug designation (ODD) from the US FDA on July 28, 2022, and fast track qualification (FTD) from the FDA on June 22, 2023. BS001 injection is the world's first oncolytic virus candidate drug that has selected type II herpes simplex virus (HSV2) as a vector and entered phase III clinical research, and has been included by the CDE as a 'breakthrough therapy variety'. In addition to BS001, Binhuai Biotech's oncolytic virus product BS006 injection has also received FDA approval for clinical research. On August 4, 2023, Binhuai Biotech obtained the 'Drug Production License' A certificate for therapeutic biological products issued by the Hubei Provincial Drug Administration, indicating its leading position in the research and development and production of oncolytic virus drugs.
Integrated production and research, ten years of forging a core technology to drive the development of the oncolytic virus industry
Binhuai Biotech's independently developed BS001 (OH2) injection has complete independent property rights, promoting the breakthrough of Chinese oncolytic viruses from 'non-existent' to 'existing'. Since its establishment, Binhuai Biotech has completed the entire process from POC to CMC to independent production, thereby realizing full closed-loop development and production of oncolytic viruses. Binhuai Biotech has advantages in the entire process of IND product application, new drug research and development lifecycle, GMP production, etc., and holds multiple core invention patents. With many advantages, it is expected to promote the progress of multiple oncolytic virus products.
About the 2023 Frost & Sullivan Life Sciences New Investment Summit Forum
The 2023 Frost & Sullivan Life Sciences New Investment Summit Forum was held on September 27th - 28th, with the theme of 'New Directions for the Future & Forge Ahead', bringing together more than 30 industry leaders, life science companies, investment institutions, and professional service agencies, focusing on new investment opportunities in life science investment and financing, and jointly discussing the capital and industrial forces for enterprises to navigate through cycles.
About the Frost & Sullivan China Leadership Award
The Frost & Sullivan China Leadership Award is an acknowledgment of an enterprise's outstanding performance and achievements in technological innovation, market potential, customer service, brand, etc. The Frost & Sullivan team has nominated a group of competitive and excellent enterprises to the independent judging panel through methods such as in-depth interviews, industry analysis, and secondary research. The independent judging panel composed of third-party investment and financing experts, financial experts, bankers, and well-known listed entrepreneurs conducts strict evaluations of the enterprises nominated by the Frost & Sullivan team, and decides to award the 'China Oncolytic Virus Therapy Leadership Award' to Wuhan Binhuai Biotechnology Co., Ltd.
